Sun Pharma strikes deal for $11.75bn acquisition of Organon

Biosimilars Collaborations and mergers News

Sun Pharma (Mumbai, India) has announced a definitive agreement to acquire US-based healthcare company Organon (NJ, USA) in a deal valued at US$11.75 billion.

The acquisition is one of the largest overseas acquisitions by an Indian pharmaceutical firm, and represents Sun Pharma’s expansion beyond its traditional generic business into higher-growth specialty segments. Organon brings a portfolio of more than 70 products spanning women’s health, biosimilars and established medicines, sold in over 140 countries.

Organon is a global healthcare company focused on improving women’s health throughout their lives, while expanding access to essential medicines globally. In women’s health, Organon develops and markets treatments for contraception, fertility and menopause, including hormonal contraceptives, as well as fertility therapies that support ovulation or embryo implantation.

At the core of Organon’s mission is the aim to close research and funding gaps in women’s health by investing in treatments and technologies that address conditions that uniquely or disproportionately affect women. This encompasses developing new therapies, but also improving access to existing treatments in lower- and middle-income countries. A second major goal is broadening access to medicines. Biosimilars, in particular, are a key part of this approach, by competing with their more expensive biologic counterparts and helping to reduce costs for healthcare systems and patients.

“This transaction represents a significant opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform. We have deep respect for Organon’s mission and look forward to building on its legacy while driving sustainable long‑term growth,” remarked Dilip Shanghvi, Executive Chairman of Sun Pharma.

You may also be interested in:

 

Click here to view the press release